
    
      This is a phaseâ… sequential-group study of ascending single and multiple oral doses
      administered to subjects with advanced solid tumors. Each subject will receive a single dose
      of Hemay020, followed by a 2-week observation period, and then will receive Hemay020
      administered once daily by mouth for 28 days. Each cycle consist of 28 days. Subjects will be
      enrolled in groups of 3 to 6. Depending on the safety and activity profile observed during
      the dose escalation phase, the dose selected for Part 2 may be adjusted. Part 2 is an
      extension part of two dose groups administered to subjects with NSCLC.
    
  